To explore whether Atorvastatin treatment of intracerebral hemorrhage can improve the clinical prognosis of patients 3 months after onset. Methods: A total of 131 patients with spontaneous intracerebral hemorrhage who underwent conservative treatment were enrolled in the study. They were randomized into the control group (n=84) and the Statin group (n=47). Both groups of patients were treated according to the Chinese intracerebral hemorrhage guidelines. The Statin group began taking 20 mg Atorvastatin calcium tablets within 24 hours of admission. The Atorvastatin was continued for 90 days at a dose of 20 mg/day. The primary outcome measures were the sequential analysis of the 90-day Modified Rankin Scale (mRS) score after randomization and the proportion of patients with adverse outcomes. Adverse outcomes were defined as death (mRS score=6 points) or major disability (mRS score=3～5 points); mRS score≤2 points was considered good clinical outcome. The secondary outcome measure was the imaging change of hematoma volume in patients after treatment. Results: In the Statin group, 31 patients (65.96% ) had good outcomes, while in the control group, 31 patients (36.90% ) had good outcomes, and this difference was statistically significant (P=0.001). Follow-up observation showed that 27 patients (32.14%) died in the control group and 6 patients (12.77% ) in the Statin group; the difference was statistically significant (P=0.014). By the end of follow-up, the adverse reactions of the Statin group and the control group were similar. No patient needed to stop drug use due to adverse reactions of Statins, and there was no significant increase in the risk of recurrent intracerebral hemorrhage in the Statin group. Conclusion: Patients with intracerebral hemorrhage who were conservatively treated with Atorvastatin within 24 hours of admission improved their prognosis at 3 months and showed no significant adverse effects.